From the Department of Carcinogenesis, University of Texas MD Anderson Cancer Center, Science Park Research Division, Smithville, Texas 78957
Received for publication, January 22, 2003
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Active caspase-9 and caspase-3 have been observed
in the mitochondria, but their origins are unclear. Theoretically,
procaspase-9 might be activated in the mitochondria in a cytochrome
c/Apaf-1-dependent manner, or activated
caspase-9 and -3 may translocate to the mitochondria, or the
mitochondrially localized procaspases may be activated by the
translocated active caspases. Here we present evidence that the
mitochondrially localized active caspase-9 and -3 result mostly from
translocation from the cytosol (into the intermembrane space) and
partly from caspase-mediated activation in the organelle rather than
from the Apaf-1-mediated activation. Apaf-1 localizes exclusively in
the cytosol and, upon apoptotic stimulation, translocates to the
perinuclear area but not to the mitochondria. In most cases, the
mitochondrially localized procaspase-9 and -3 are released early during
apoptosis and translocate to the cytosol and/or perinuclear area.
Cytochrome c and the mitochondrial matrix protein Hsp60 are
also rapidly released to the cytosol early during apoptosis. Both the
early release of proteins like cytochrome c and Hsp60 from
the mitochondria as well as the later translocation of the active
caspase-9/-3 are partially inhibited by cyclosporin A, an inhibitor of
mitochondrial membrane permeabilization. The mitochondrial active
caspases may function as a positive feedback mechanism to further
activate other or residual mitochondrial procaspases, degrade
mitochondrial constituents, and disintegrate mitochondrial functions.
Apoptosis plays an essential role in animal development and in
maintaining the homeostasis of adult tissues (1). The family of
caspases (cysteine aspartic acid-specific
protease) is the key effector in the execution
of apoptotic cell death (2). Caspases are synthesized as inactive
proenzymes, which become proteolytically cleaved during apoptosis to
generate active enzymes. The active caspases cleave cellular proteins
such as poly(ADP-ribose) polymerase
(PARP)1 to dismantle the
apoptotic cells (3). The exact mechanism(s) whereby various caspases
become activated are still unclear. Two pathways leading to caspase
activation are relatively better understood. In the first pathway,
apoptotic stimuli cause the release of cytochrome c (cyt. c)
from the intermembrane space (IMS) of the mitochondria to the cytosol.
The released cyt. c binds to and activates the adaptor protein Apaf-1,
which in turn activates the initiator procaspase-9 in the presence of
ATP, leading to the formation of apoptosome and subsequent activation
of "executioner" caspases such as caspase-3, -6, or -7 (4). In the
second pathway, the FADD/TRADD adaptor proteins recruit the initiator
procaspase-8 (or -10) to cell surface death receptors, leading to death
receptor-induced signaling complex formation, caspase-8 activation,
and, subsequently, activation of executioner caspases (5). Recent
evidence also implicates caspase-2 activation upstream of the cyt.
c/Apaf-1 apoptosome-initiated apoptosis (6-10) or cyt.
c/Apaf-1-independent apoptotic pathways (11-13).
Apart from their cytosolic residence, procaspases are also localized in
other subcellular compartments. For example, procaspase-2 has been
found in the Golgi apparatus and nucleus (14, 15). Procaspase-12 is
mainly expressed in the endoplasmic reticulum where it serves as a
major sensor of local stress (16). Depending on cell types,
procaspase-2 (17), procaspase-3 (18, 19), procaspase-8 (20), and
procaspase-9 (17, 21) have been reported to be present in the IMS of
the mitochondria. Active caspases have also been found in different
subcellular compartments. For example, in response to tumor necrosis
factor- Recently, we have found that apoptosis induced by many stimuli involves
an early mitochondrial activation, which is characterized by
up-regulation of the mitochondrial respiratory chain (MRC) proteins and
many other mitochondrially localized non-MRC proteins (30). A cardinal
feature of this mitochondrial activation-dependent apoptotic pathway (or MADAP) is the early up-regulation and enrichment of cyt. c in the mitochondria, which precede its release. Because procaspase-9 is present in the IMS of the mitochondria (14, 17, 21), we
hypothesized that the increased mitochondrial cyt. c might lead to the
activation of procaspase-9 and, subsequently, of procaspase-3 inside
the organelle. In this study, we utilized our MADAP model to test this
hypothesis. Our results show no evidence of cyt. c/Apaf-1-mediated
procaspase-9 activation inside the mitochondria. Instead, the results
suggest that the mitochondrial active caspase-9 and -3 result mostly
from the translocation from the cytosol and partly from
caspase-mediated activation in the mitochondria.
Cells and Reagents--
GM701.2-8C (GM701) cells were kindly
provided by Dr. M. King (Thomas Jefferson University) and cultured in
Dulbecco's minimum essential medium (Invitrogen) supplemented with
10% heat-inactivated fetal bovine serum and antibiotics. Human
prostate cancer cells, PC3 and LNCaP, were purchased from ATCC
(Manassas, VA) and cultured in RPMI 1640 supplemented with 5 and
10% fetal bovine serum, respectively.
The primary antibodies used are listed in Table
I. All secondary antibodies,
i.e. goat, donkey, or sheep anti-mouse or rabbit or goat IgG
conjugated to horseradish peroxidase, fluorescein isothiocyanate, or
rhodamine, together with enhanced chemiluminescence (ECL) reagents were
acquired from Amersham Biosciences. Biotinylated goat anti-rat or
anti-rabbit antibodies were obtained from Jackson ImmunoResearch (West
Grove, PA). Fluorogenic caspase substrates DEVD-AFC and LEHD-AFC,
Pan-caspase inhibitor Z-VAD-fmk, caspase-3/7 inhibitor Z-DEVD-fmk, and recombinant caspase-3 were bought from Biomol
(Plymouth Meeting, PA). Streptavidin conjugated to AlexaFluor 594 or
488 and mitochondrial dyes were purchased from Molecular Probes
(Eugene, OR). All other chemicals were purchased from Sigma unless
specified otherwise.
Subcellular Fractionation and Western Blotting--
Mitochondria
were prepared as described previously (30-32). Briefly, cells were
treated with various chemicals, inhibitors, or vehicle (ethanol or
Me2SO) control. In some experiments, cells were pretreated
with cyclosporin A (CsA), Z-VAD-fmk, or Z-DEVD-fmk before apoptosis
induction. At the end of the treatment, cells were harvested with
trypsin, washed twice in ice-cold PBS, and resuspended in 600 µl of
homogenizing buffer (20 mM HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM sodium EGTA, and 1 mM dithiothreitol) containing 250 mM sucrose
and a mixture of protease inhibitors (1 mM
phenylmethylsulfonyl fluoride, 1% aprotinin, 1 mM
leupeptin, 1 µg/ml pepstatin A, and 1 µg/ml chymostatin). After 30 min of incubation on ice, cells were homogenized in the same buffer
using a glass Pyrex homogenizer (type A pestle, 140 strokes). Unbroken
cells, large plasma membrane pieces, and nuclei were removed by
centrifuging the homogenates at 500 × g for 5 min at
4 °C. The resulting supernatant was centrifuged at 10,000 × g for 20 min to obtain mitochondria. The remaining
supernatant was again subjected to centrifugation at 100,000 × g for 1 h to obtain the cytosolic fraction
(i.e. S100 fraction). Mitochondrial pellet was washed three
times in homogenizing buffer and then solubilized in TNC buffer (10 mM Tris acetate, pH 8.0, 0.5% Nonidet P-40, 5 mM CaCl2) containing protease inhibitors.
Protein concentration was determined by Micro-BCA kit (Pierce).
For Western blotting, various amounts of mitochondrial or cytosolic
proteins were loaded in each lane of a 15% SDS-polyacrylamide gel.
After gel electrophoresis and protein transfer, the membrane was probed
or reprobed, after stripping, with various primary and corresponding
secondary antibodies. Western blotting was performed using ECL as
described previously (30).
Characterization of Mitochondrial Preparation by Transmission
Electron Microscopy--
The mitochondrial fractions prepared from PC3
cells as described above were fixed for 30 min at 4 °C in 1%
acrolein (v/v) in homogenizing buffer. At the end of fixation, the
mitochondria were pelleted by centrifugation at 10,000 × g and then resuspended in homogenizing buffer containing
0.5% dimethyl sulfoxide (v/v). Mitochondria were pelleted and
resuspended in the same buffer four times for 15 min each, post-fixed
for 30 min in 1% osmium tetroxide at room temperature, washed in
homogenizing buffer, dehydrated in graded ethanol (20, 40, 60, 80, 90, 95, and 100% 2 times), and then passed through propylene oxide,
followed by infiltration and embedding in epoxy resin. Ultrathin
(80-100-nm) sections were cut with a Reichert Ultracut E
ultramicrotome, picked up on 200 mesh copper grids, and stained with
2% (w/v) aqueous uranyl acetate followed by lead citrate. Grids were
examined and photographed in a Zeiss 10 C transmission electron
microscopy at an accelerating voltage of 80 kV.
Preparation of Percoll Gradient-purified Mitochondria--
PC3
cells (12 × 106) were treated with ethanol or BMD188
(40 µM) for 1 h and then harvested for
homogenization and differential centrifugation as described above. The
resulting 10,000 × g mitochondrial pellet was washed
and then resuspended in an EDTA-free medium and layered on a Percoll
gradient consisting of four layers of 10, 18, 30, and 70% (by volume)
Percoll in 0.3 M mannitol and 5 mM MOPS, pH 7.2 (33). After centrifugation for 35 min at 13,500 × g,
the purified mitochondria were separated from non-mitochondrial membranes and non-functional organelles and collected at the 30/70% interface and washed with 0.3 M mannitol, 5 mM
MOPS, pH 7.2, containing 1 mg/ml bovine serum albumin to remove the Percoll.
PARP Cleavage--
PARP cleavage assays were performed as
described previously (30-32).
Quantification of Apoptotic Nuclei Using DAPI
Staining--
Cells were plated on glass coverslips (4 × 104 cells/18-mm2 coverslip) the day before
treatment. The next day, cells were treated with vehicle control
(i.e. ethanol or Me2SO) or various inducers. Thereafter, cells were incubated live with DAPI (0.5 µg/ml) for 10 min at 37 °C followed by washing. The percentage of cells exhibiting apoptotic nuclei, as judged by chromatin condensation or nuclear fragmentation, was assessed by fluorescence microscopy (34). An average
of 600-700 cells was counted for each condition.
DEVDase and LEHDase Activity Measurement--
Cells were washed
twice in PBS and the whole cell lysate was made in the lysis buffer (50 mM HEPES, 1% Triton X-100, 0.1% CHAPS, 1 mM
dithiothreitol, and 0.1 mM EDTA). For activity measurement, 30 or 100 µg whole cell lysate, mitochondria, or cytosol was added to
a reaction mixture containing 10 or 30 µM fluorogenic
peptide substrates, Ac-DEVD-AFC or Ac-LEHD-AFC, 50 mM
HEPES, pH 7.4, 10% glycerol, 0.1% CHAPS, 100 mM NaCl, 1 mM EDTA, and 10 mM dithiothreitol, in a total
volume of 1 ml and incubated at 37 °C for 1 h. Production of
7-amino-4-trifluoromethylcoumarin (AFC) was monitored in a spectrofluorimeter (Hitachi F-2000 fluorescence spectrophotometer) using excitation wavelength 400 nm and emission wavelength 505 nm. The
fluorescent units were converted into nanomoles of AFC released per h
per mg of protein using a standard curve. The results were generally
presented as fold activation over the control (30). In some
experiments, the DEVDase activity was continuously monitored over a
period of 2 h.
Cell-free Caspase Activation in the Mitochondrial
Fractions--
Mitochondria and cytosol were prepared from treated or
untreated PC3 cells as described above. Various amounts of freshly isolated, unlysed or lysed (using the TNC buffer) mitochondria were
co-incubated with 100 µg of cytosol freshly prepared from untreated
PC3 cells for 1 h at 37 °C. At the end, either 10 or 30 µM DEVD-AFC substrate was added to the mixture, which was
further incubated for 1 h at 37 °C. Subsequently, the DEVDase
activity in the co-incubates was measured.
Kinetic Study of Caspase Activation--
Two sets of PC3 cells
(107 each) were simultaneously treated with 40 µM BMD188 for 0, 30, 45, 60, 90, and 120 min. At the end, one set of cells was harvested for the preparation of whole cell lysate
and the other set harvested for subcellular fractionation, as described
above. Subsequently, the three preparations, i.e. whole cell
lysate, cytosol, and mitochondria, all derived from 107
cells, were used to measure the caspase activity by incubating with 10 µM of the Ac-DEVD-AFC substrate, as detailed above.
Immunostaining of Caspases and Apaf-1--
Cells grown on glass
coverslips were treated for various time intervals. Fifteen min prior
to the end of the treatment, cells were incubated live with DAPI to
label apoptotic nuclei (30). Then cells were fixed in 4%
paraformaldehyde for 10 min followed by permeabilization in 1% Triton
X-100 for 10 min. After washing in PBS, cells were first blocked in
10% goat whole serum for 30 min at 37 °C and then probed with
Apaf-1, caspase-9, or caspase-3 (all at 1:500) for 1 h at
37 °C. After washing in PBS, cells were incubated with biotinylated
goat anti-rat or anti-rabbit IgG antibody (1:1000). Finally, cells were
incubated with streptavidin-AlexaFluor 488 or 594 (1:500) for 1 h
at 37 °C. After thorough washing, coverslips were mounted on slides
using Vectashield mounting medium (Vector Laboratories, Inc.,
Burlingame, CA) and observed under an Olympus BX40 epifluorescence
microscope. Images were captured with MagnaFire software and
processed in Adobe Photoshop.
Proteinase K Digestion of Isolated Mitochondria--
Freshly
isolated mitochondria (100 µg) were incubated in the homogenizing
buffer (without protease inhibitors) alone or in the presence of
proteinase-K (0.1 µg/ml) only or proteinase K plus Triton X-100 (1%
final concentration). After 10 min of incubation on ice, 2 µl of
phenylmethylsulfonyl fluoride (100 µM) was added to
terminate proteolysis followed by addition of 6× SDS-loading buffer.
Samples were then boiled for 5 min and analyzed immediately by Western
blotting (20).
Alkali Extraction of the Mitochondria--
The mitochondrial
pellet (100 µg) was suspended in 0.1 M
Na2CO3, pH 12.0, and incubated on ice for 30 min. At the end of the incubation, the sample was centrifuged at
100,000 × g for 1 h. The resulting pellet was
then lysed in the TNC buffer. Both supernatant and pellet were then
subjected to Western blotting (35).
Cell-free Caspase Activation and Translocation
Experiments--
All cell-free reactions were performed in
homogenizing buffer in a total volume of 100 µl. Freshly isolated
cytosol and/or mitochondria were incubated at 37 °C for 2 h
with addition of bovine cyt. c (50 µg/ml) (36, 37). At the end,
samples containing co-incubated mitochondria were centrifuged at
10,000 × g for 20 min to obtain the mitochondrial
pellet. The resulting pellet was washed twice and suspended in
homogenizing buffer. For translocation studies, cyt. c-activated
cytosol was further incubated with untreated mitochondria for 1 or
3 h at 37 °C followed by centrifugation (10,000 × g) for 20 min. Following two washes in homogenizing buffer,
the mitochondrial pellet, together with the supernatant, was subjected
to Western blotting. In separate sets of experiments, isolated cytosol
or mitochondria from BMD188 (40 µM) treated or untreated
cells were co-incubated in various combinations for 1 or 2 h at 4, 25, and 37 °C. After co-incubation, the pelleted mitochondria were
washed twice with homogenizing buffer, and then equal amounts of
proteins were separated followed by Western blotting. To determine
whether the mitochondrially localized procaspases can ever
be activated in the organelle, mitochondria were incubated in the
homogenizing buffer for 2 h at 37 °C by addition of recombinant caspase-3 (1 µM) or caspase-9 (1 µM). At
the end of the incubation, the mitochondria were pelleted, washed twice
in homogenizing buffer, and resuspended in 100 µl of homogenizing
buffer. The supernatant and pellet were then subjected to SDS-PAGE and
Western blotting analysis.
Activated Mitochondria Possess Caspase Activity--
Apoptosis
induced by multiple stimuli is preceded by a rapid up-regulation and
accumulation of cyt. c in the mitochondria (30). Because many
procaspases are localized in the mitochondria (see Introduction), we
reason that some of these mitochondrially localized procaspases, in
particular procaspase-9 and procaspase-3, might become activated in the
organelle in a cyt. c-dependent manner, analogous to
apoptosome-mediated activation of procaspase-9 and -3 in the cytosol.
To test this possibility, we used BMD188, a cyclic hydroxamate that
activates MADAP in multiple cell types (30-32), to treat PC3 prostate
epithelial cancer cells. Following treatment for various time
intervals, whole cell lysate, and mitochondrial and cytosolic fractions
were prepared from equal numbers of cells (i.e.
107 cells for each fraction), and the DEVDase activity,
which measures caspase-3 and -7 activation, was determined. The quality
of subcellular fractionation was monitored by Western blot analysis of
known compartment-specific proteins: cytochrome c oxidase
subunit II for mitochondria, lamin A/C for nuclei, and lactate
dehydrogenase for cytosol. We did not detect any cross-contamination
among different fractions (see Refs. 30 and 32, and data not shown).
Electron microscopy analysis also revealed pure mitochondria in our
preparations (not shown). As shown in Fig.
1A, 45 min post-BMD188
treatment of PC3 cells, about 4- and 2-fold DEVDase activity was
observed in the whole cell lysate and mitochondria, respectively. Only marginal DEVDase activity was detected in the cytosol by this time
(Fig. 1A). By 60-120 min, increased DEVDase activity was observed in the cytosol, but the corresponding mitochondrial DEVDase activity was still higher (Fig. 1A). As expected, the
DEVDase activity was always the highest in the whole cell lysate (Fig. 1A).
Next, we further examined the DEVDase activity in the mitochondrial
fractions using a cell-free system. Mitochondria and cytosol were
isolated from 1.5-h BMD188-treated or untreated PC3 cells and used in
DEVDase activity measurements. Untreated mitochondria, either lysed
(with Nonidet P-40) or unlysed, had negligible caspase activity (Fig.
1B, lanes 1 and 2). Untreated cytosol
consistently showed slightly higher basal level DEVDase activity (Fig.
1B, lane 5), which did not change when
co-incubated with untreated mitochondria (Fig. 1B,
lanes 6 and 7). When the mitochondria from BMD188-treated PC3 cells were co-incubated with untreated cytosol, significantly increased DEVDase activity was observed (Fig.
1B, lanes 8 and 9; note that higher
DEVDase activities were observed in these experiments than in Fig.
1A because higher amounts (i.e. 100 µg) of
protein and substrate (30 µM) were used). Our initial interpretation was that cyt. c released from the BMD188-activated mitochondria caused caspase activation in the cytosol. Surprisingly, however, when the activated mitochondria were directly used in DEVDase
activity measurement, in the absence of untreated cytosol, essentially
similar levels of increased DEVDase activity were observed (Fig.
1B, compare lanes 3 and 4 versus lanes 8 and 9). In both cases,
Nonidet P-40-lysed mitochondria gave rise to higher DEVDase activities
(Fig. 1B, lane 4 versus lane 3 and
lane 9 versus lane 8). As expected,
both Z-DEVD-fmk, a caspase-3/7-specific inhibitor, and Z-VAD-fmk, a
pan-caspase inhibitor, inhibited the mitochondrial
and cytosolic DEVDase activity (Fig. 1C), just as both
inhibited the BMD188-induced apoptosis (30, 32). Collectively, the data
in Fig. 1 suggest that the BMD188-activated mitochondria possess
DEVDase activity, which most likely reside in the IMS as evidenced by
the increased activities upon Nonidet P-40 lysis.
To characterize further the DEVDase activity associated with the
BMD188-activated mitochondria, we purified mitochondria using the
Percoll gradient and the corresponding cytosol from control or 1.5-h
BMD188-treated PC3 cells and incubated them with DEVD-AFC substrate
in vitro at 37 °C for a continuous period
(i.e. from 0 to 120 min). The caspase activity was then
plotted as either raw fluorescence, fold activation, or corrected
fluorescence as a function of incubation time. As shown in Fig.
2, BMD188-activated mitochondria
demonstrated a time-dependent increase in caspase activity.
When expressed as raw fluorescence, the cytosol samples possessed
higher fluorescence values than the corresponding mitochondrial samples
at all time points (Fig. 2A). However, cytosol samples also
possessed higher background (i.e. time 0) fluorescence
values (see Fig. 2 legend). Therefore, when plotted as fold
activation (Fig. 2B) or corrected fluorescence (Fig.
2C), the mitochondrial samples demonstrated higher DEVDase
activities than did the corresponding cytosolic samples.
Similar DEVDase activity was also detected in the mitochondrial
fractions in several other MADAP models (30) including PC3 cells
treated with butyrate, GM701 cells treated with BMD188, LNCaP cells
subjected to serum starvation, and MDA-MB-231 cells treated with
etoposide (not shown).
Detection of Proteolytically Activated Caspase-9 and Caspase-3 in
the Mitochondria during Apoptosis--
In principle, the DEVDase
activity in the activated mitochondria may result from either
procaspases becoming activated in the mitochondria or activated
caspases translocating to the organelle, or both. We explored these
possibilities by focusing on the activation of procaspase-9 and -3, two
pivotal caspases in the apoptosome pathway initiated by cyt. c and
Apaf-1.
In PC3 cells, significant amounts of procaspase-9 and procaspase-3 were
localized in the mitochondria (Fig.
3A). Procaspase-9 (~46 kDa)
is activated mostly through autoactivation via Apaf-1-mediated oligomerization, resulting in proteolytic cleavage at
Asp315 to generate a 35-kDa fragment (p35) containing the
caspase recruitment domain and the large subunit (38) and to expose the
ATPF motif in the N terminus of the linker region to interact with XIAP
and Smac/Diablo (39, 40). Partially activated caspase-9 activates caspase-3, which in turn can cleave procaspase 9 at
Asp330 to generate a 37-kDa fragment (p37) (containing the
caspase recruitment domain, large subunit, and the linker region) and
~10-kDa small subunit (38-41). In our experiments, we utilized an
antibody that recognizes both the proform and the p37/p35 bands (Table
I). As shown in Fig. 3A, 45 min post-BMD188 treatment, the
mitochondrial procaspase-9 protein level was significantly reduced
without the appearance of the p37/p35 bands, suggesting that, by this
time point, the majority of the mitochondrial procaspase-9 was probably released from rather than activated in the organelle. Indeed, at 45 min, increased procaspase-9 was observed in both cytosol (Fig.
3A) and perinuclear area (see below). Also, the LEHDase assays did not detect caspase-9 activity (not shown).
In the cytosol, caspase-9 cleavage was observed at 45 min (Fig.
3A). By 1 h, the maximum level of caspase-9 cleavage
products was observed in the cytosol (Fig. 3A). In the
meantime, the p37/p35 bands began to appear in the mitochondria (Fig.
3A), suggesting that, in BMD188-treated PC3 cells,
procaspase-9 became activated first in the cytosol and then the
activated caspase-9 translocated to the mitochondria. In support,
between 1 and 4 h, decreased amounts of activated caspase-9 were
observed in the cytosol (Fig. 3A). At the same time,
increasing levels of the p37/p35 products in the mitochondria were
observed, whereas the mitochondrial procaspase-9 bands remained fairly
constant (Fig. 3A). Interestingly, a prominent ~36-kDa
protein band was detected by the anti-caspase-9 antibody only in the
mitochondria, which began to decrease at 1 h and disappeared by
4 h after BMD188 treatment (Fig. 3A). Whether this band
represents a caspase-9 isoform (42, 43) or just a nonspecific protein remains to be determined.
Procaspase-3 (~32 kDa) is generally first cleaved by caspase-8,
caspase-9, caspase-10, or granzyme-B at Asp175 to generate
the p12 small subunit and the ~p24 large subunit that still contains
the pro-domain. Then the p24-p12 complex is further cleaved at
Asp9, possibly through its auto-catalytic activity, to
generate p20, which could be further cleaved at Asp28 to
produce the p17 fragment (41, 44, 45). Frequently, a p31 fragment can
also be detected, resulting from the procaspase-3 removed of the first
9 amino acids in the pro-domain. Various experiments have demonstrated
that the p20/p17/p12 bands represent catalytically active caspase-3
(44, 45). We utilized an antibody that recognizes both procaspase-3 and
most cleavage products (Table I). In BMD188-treated PC3 cells, similar
to caspase-9, the mitochondrial procaspase-3 was significantly reduced
at 45 min (Fig. 3A). Different from caspase-9 by 45 min, the
p20 and the p17 caspase-3 bands were detected simultaneously in the
cytosol and mitochondria (Fig. 3A). By 1 h when
significant amounts of caspase-3 activation occurred in both cytosol
and mitochondria (Fig. 1 and Fig. 3A), PARP cleavage was
observed, and 55% of the cells became apoptotic (Fig. 3A). Caspase-3 cleavage overall paralleled the DEVDase activity (Fig. 1). Of
interest, the anti-caspase-3 antibody also detected an unknown
~19-kDa band in untreated cytosol and mitochondria, which decreased
as apoptosis proceeded (Fig. 3A).
To determine whether appearance of the activated caspases in the
mitochondrial fraction is cell type-specific, we treated GM701
fibroblasts with BMD188. As in BMD188-treated PC3 cells, the
mitochondrial procaspase-9 and, in particular, procaspase-3 were
decreased by 30 min (Fig. 3B). Whereas the maximum decrease of procaspase-9 was observed by 30 min, the procaspase-3 level continued to decrease until the end of the treatment, i.e.
4 h (Fig. 3B). Activated forms of caspase-9 and
caspase-3 were simultaneously detected at 2 h post-BMD188
treatment when PARP was cleaved and 56% cells were apoptotic (Fig.
3B). At 2 h, the p37/p35 caspase-9 fragments were
detected in the mitochondria without an obvious decrease in the
intensity of the mitochondrial procaspase-9 band (Fig. 3B),
suggesting that, as in the BMD188-treated PC3 cells, the mitochondrial
activated caspase-9 resulted, most likely, from translocation from the
cytosol. In support, 4 h post-treatment, most procaspase-9 became
cleaved in the cytosol, but the p37/35 bands actually decreased
compared with those at 2 h (Fig. 3B). In the meantime,
the p37/p35 bands in the mitochondria significantly increased without a
corresponding decrease of the proform (Fig. 3B), strongly
suggesting that the activated caspase-9 in the cytosol had translocated
to the mitochondria. Again, as observed in PC3 cells, caspase-3
activation was observed simultaneously in the cytosol and mitochondria
(Fig. 3B). Although the mitochondrial procaspase-3 decreased
at 30 min and further decreased at 1 h, no cleavage products were
observed at these time points (Fig. 3B). The anti-caspase-9
and anti-caspase-3 antibodies again detected the ~36- and ~19-kDa
bands, respectively, more obviously in the mitochondrial fractions
(Fig. 3B). Accompanying the cleavages of procaspase-9 and
procaspase-3, increased LEHDase (~2-fold increase) and DEVDase (up to
8-fold increase) activities were detected in both cytosolic and
mitochondrial fractions (not shown).
In both PC3 epithelial cells and GM701 fibroblasts treated with BMD188,
we observed an early decrease of procaspase-9 and/or -3 in the
mitochondria without concomitant cleavage (Fig. 3, A and
B), suggesting that the mitochondrial procaspases may have been released from the organelle into the cytosol or other subcellular compartments, as observed in other apoptosis models (17-19, 21, 22).
We carried out an immunofluorescence experiment in GM701 (Fig.
4) and PC3 (not shown) cells to explore
this possibility. Procaspase-9 and -3 were homogeneously distributed in
GM701 cells (Fig. 4, A and E; note that the
mitochondrial localization of these procaspases was not very obvious
due to their overwhelming expression in the cytosol). By 30 min (not
shown) or 1 h (Fig. 4, B and F) post-BMD188
treatment, there was a prominent increase of both caspase-9 and
caspase-3 staining in the nuclear area in most of the cells. Since by
30 min to 1 h there was no caspase-9 or caspase-3 activation in
BMD188-treated GM701 cells revealed either by Western blotting (Fig.
3B) or by activity assays (Ref. 30; data not shown), the
increased staining in the nuclear area therefore most likely resulted
from the procaspase, rather than the active caspase, translocation from
the mitochondria. Another piece of supporting evidence for this
conclusion was that all cells that showed perinuclear staining of
caspases were healthy and alive (Fig. 4, A-H), and only
~10% of the cells were apoptotic at this time frame (Fig.
3B) (30), thus suggesting that the caspases had not been
activated. The increased perinuclear staining of procaspases-9 or -3 generally was slightly larger than the DAPI staining (e.g.
compare Fig. 4, B and F versus
D and H), suggesting that the translocated
procaspases were perhaps clustered outside the organelle.
To determine whether inducers other than BMD188 also can induce
association of activated caspase-9 and -3 with the mitochondria, we
subjected LNCaP cells to serum starvation, a MADAP model involving an
early mitochondrial activation (30). As shown in Fig. 3C, activated caspase-9 and -3 were detected in the cytosol as well as in
the mitochondria on day 6, when PARP was cleaved and 55% of the cells
were apoptotic. In LNCaP cells there was only low levels of
procaspase-9 in the mitochondria (Fig. 3C). When cytosolic procaspase-9 was cleaved on day 6, the p35 band was preferentially observed in the mitochondria, whereas the p37 band was most prominent in the cytosol (Fig. 3C). On day 8 when most cytosolic
procaspase-9 was processed, essentially no p37/p35 bands were detected
in the cytosol, whereas increased levels of both bands were seen in the mitochondria (Fig. 3C). These results once again suggest
that the mitochondrial active caspase-9 most likely results from the translocation of the proteolytically activated caspase-9 in the cytosol. There was a slight decrease in the mitochondrial procaspase-9 in LNCaP cells starved for 8 days (Fig. 3C), raising the
possibility that during late apoptosis the mitochondrial procaspase-9
might be activated in situ. Different from procaspase-9,
LNCaP cells expressed abundant procaspase-3 in the mitochondria, which
showed a time-dependent decrease, similar to cytosolic
procaspase-3 (Fig. 3C). By day 6 when PARP was cleaved,
decreased procaspase-3 and increased active p17 fragments were observed
in both cytosol and mitochondria (Fig. 3C). By day 8 when
most PARP was degraded, a further decrease of procaspase-3 and increase
in the p20/p17 fragments were observed in both compartments. However,
the increase of the p17 active caspase-3 in the mitochondria was much
more prominent than that in the cytosol (Fig. 3C).
Similarly, in MDA-MB-231 breast cancer cells treated with etoposide,
yet another MADAP model (30), we also observed activated caspase-9 and
caspase-3 in the mitochondria (not shown).
To determine whether only MADAP inducers could cause association of
active caspases with the mitochondria, we treated GM701 cells with
staurosporine, which causes cell death independently of MRC functions
and without mitochondrial activation (30, 32). As shown in Fig.
3D, although there was no early exodus of mitochondrially localized procaspase-9 or -3, activated forms of both caspases were
detected in the mitochondria, simultaneously with their activation in
the cytosol, PARP cleavage, and increased apoptosis.
The conclusions from the above experiments are as follows. 1) The
presence of the activated caspase-9 and -3 seems to be a general
phenomenon during apoptosis. 2) The mitochondrial caspase-9 activation
generally appears either after the cytosolic caspase-9 activation (Fig.
3A) or concomitant with the cytosolic caspase-9 activation.
In the latter case, the first appearance of the activated caspase-9 in
the mitochondria is rarely accompanied by a decrease in the
corresponding proform, whereas the first appearance of the activated
caspase-9 in the cytosol is always accompanied by a decrease in
procaspase-9 (Fig. 3, B-D). Late in apoptosis, however, the
increased active caspase-9 levels in the mitochondria may (Fig. 3,
C and D, the last lanes) or may not
(Fig. 3, A and B, the last lanes) be
accompanied by a decrease in the mitochondrial procaspase-9. These
results suggest that the mitochondrial active caspase-9 may initially
come from translocation from the cytosol but, late during apoptosis,
the increased activated caspase-9 in the mitochondria may result from
translocation and/or caspase-mediated activation in the organelle. 3)
Activated caspase-3 is always detected simultaneously in the
mitochondria and cytosol concomitant with the caspase-9 activation in
the cytosol (Fig. 3, A-D), raising a similar possibility
that the activated caspase-3 in the mitochondria may result from
translocation and/or caspase-mediated activation in the organelle.
Apaf-1 Localizes Exclusively in the Cytosol and Translocates to
the Perinuclear Area during Apoptosis--
The second point mentioned
above suggests that the initiator caspase, caspase-9, may not be
activated in the organelle in a cyt. c/Apaf-1-dependent
manner. Theoretically, if procaspase-9 were activated inside the
mitochondria in an apoptosome-dependent manner, Apaf-1
should be expressed in the mitochondria. Western blot analysis
indicated that, in all cells studied, Apaf-1 was expressed exclusively
in the cytosol (Fig. 3 and data not shown), consistent with an earlier
report (46). Upon apoptosis induction, Apaf-1 showed a rapid and
time-dependent decrease (Fig. 3, A-D). Immunofluorescent labeling revealed that Apaf-1, much like the mitochondrial procaspase-9 and -3 (Fig. 4, A-H),
translocated to the perinuclear area in GM701 (Fig. 4, I-L)
or PC3 (not shown) cells treated with BMD188 or in serum-starved LNCaP
cells (not shown). In multiple Western and immunolabeling experiments,
we failed to observe translocation of Apaf-1 to the mitochondria upon
apoptosis induction (Fig. 3 and 4; data not shown). These observations
suggest that procaspase-9 is unlikely to be activated in the
mitochondria in a cyt. c/Apaf-1-dependent manner.
Active Caspases Are Located in the IMS of the
Mitochondria--
Next, we utilized the mitochondria from the
BMD188-treated (3 h) or untreated GM701 cells to determine where the
active caspases were located in the mitochondria, i.e. on
the outer mitochondrial membrane (OMM) or in the IMS. When control
mitochondria were treated with proteinase K alone, the procaspase-9 and
procaspase-3 bands were detected (Fig.
5A, lanes 1 and
2). When the mitochondria were treated with proteinase K in
the presence of Triton X-100 (to solubilize the organelle),
procaspase-9 was completely degraded, whereas procaspase-3 was degraded
into two specific fragments (Fig. 5A, lane 3).
These results were consistent with these procaspases being located in
the IMS (17-19, 21, 22). Likewise, when the BMD188-activated
mitochondria were treated with proteinase K alone, the active caspase-9
(p37/p35) or caspase-3 (p17) bands were not significantly affected
(Fig. 5A, lane 5). When these mitochondria were
treated with proteinase K together with Triton X-100, both the pro- and
active forms were degraded (Fig. 5A, lane 6; note that the bands marked by the dotted circles were a
proteinase K degradation product rather than p17). These results
suggest that the active caspase-9 and -3 were also present in the IMS. As an experimental control, voltage-dependent anion channel
or VDAC, a protein mostly localized in the OMM with a small part of the
molecule protruding to the cytosol (47, 48), was not digested by
proteinase K treatment alone (Fig. 5A, lane 2)
but mostly degraded after solubilization with Triton X-100 (Fig.
5A, lanes 3 and 6). Note that
proteinase K treatment alone appeared to have partially digested both
caspase-9 and caspase-3 as well as VDAC in the BMD188-treated
mitochondria (Fig. 5A; compare lanes 5 versus lanes
4), which was consistent with the observations that the 3-h
BMD188-activated mitochondria had significant mitochondrial membrane
permeabilization or MMP (30) thus allowing partial access of proteinase
K to the IMS.
In another set of experiments, we utilized a different strategy to
confirm the IMS localization of the activated caspase-9 and caspase-3
in the mitochondria. Specifically, we adopted an alkali extraction
protocol to strip the proteins localized either peripheral or integral
to the OMM, depending on the harshness of the extraction conditions. As
shown in Fig. 5B, under our experimental conditions, VDAC,
an OMM protein, was extracted from the mitochondria but Hsp60, a
mitochondrial matrix protein, was not. Under the same conditions, both
pro- and the activated forms of caspase-9 and caspase-3 remained in the
mitochondrial pellet (Fig. 5B), thus confirming that the
activated caspases were localized in the IMS. Note that in both
experiments BMD188 treatment resulted in an up-regulation of VDAC (Fig.
5A, lane 4 versus lane 1; Fig. 5B, lane 3 versus lane 1),
consistent with our previous observations that MADAP inducers such as
BMD188 systematically up-regulate MRC proteins as well as
mitochondrially localized non-MRC proteins (30).
Association of Active Caspases with the Mitochondria Is Inhibited
by CsA--
In the following experiments, we addressed how the
activated caspase-9 and -3 might end up in the IMS of the mitochondria. First, we utilized the BMD188-treated PC3 cells to assess the relationship between mitochondrial protein release, caspase activation, and caspase association with the mitochondria. Western blotting using a
monoclonal anti-cyt. c antibody that specifically recognizes holo-cyt.
c (30) revealed significant release of holo-cyt. c from the
mitochondria as early as 5 min post-treatment (Fig.
6). By 15 min cyt. c release reached the
peak level (Fig. 6). By 2 h, cyt. c accumulation in the cytosol
decreased (Fig. 6) probably due to extensive cell death by this time
(Fig. 3A) leading to cyt. c leak into the culture medium
(30, 49). Note that this antibody somehow did not react well with the
holo-cyt. c in the mitochondrial fraction in certain cell types (Fig. 6
and data not shown). Surprisingly, the 60-kDa mitochondrial matrix
protein Hsp60 was also rapidly released; the release was observed as
early as 5 min and peaked at ~30 min (Fig. 6). The release of both
cyt. c and Hsp60 occurred before the activated caspase-9 and -3 appeared in the mitochondria at ~1 h (Fig. 6). The release of both
cyt. c and Hsp60 was inhibited (i.e. delayed) by CsA, an
inhibitor of MMP (48), but not by Z-VAD, a general caspase inhibitor
(Fig. 6). Interestingly, CsA also appeared to decrease the levels of active caspase-9 and caspase-3 specifically in the mitochondria, especially at 1 h post-treatment (Fig. 6). By contrast, Z-VAD inhibited activation of caspase-9 and, more prominently, of caspase-3, leading to significantly reduced levels in both cytosol and
mitochondria (Fig. 6). Together, these results suggest that 1)
perturbation of the mitochondrial integrity, as evidenced by cyt. c and
Hsp60 release, occurs prior to caspase activation and their association with the mitochondria; 2) a CsA-inhibitable mechanism(s) is involved in
the initial mitochondrial protein release; and 3) a similar CsA-inhibitable mechanism(s) might also be involved in the later association of the activated caspases in the mitochondria.
Mitochondrially Localized Active Caspases Result Mostly from
Translocation and Partly from in Situ Activation--
Next, we
performed several sets of cell-free experiments to further address how
the active caspases in the mitochondria may have originated. In the
first set (Fig. 7, A and
B, lanes 1-4), mitochondria or cytosol prepared from
untreated GM701 cells were activated with cyt. c. As shown in Fig.
7A (lane 4), cyt. c caused complete proteolysis
of procasapse-9 in the cytosol generating prominent p37/p35 bands.
Similarly, stimulation of the cytosol with cyt. c activated caspase-3
to generate the p24/p20/p17 bands (Fig. 7B, lane
4). In contrast to cytosolic procaspases, neither the
mitochondrial procaspase-9 nor the mitochondrial procaspase-3 was
proteolytically activated by cyt. c (Fig. 7, A and
B, lanes 2), confirming that there is no Apaf-1
in the mitochondria.
In the second set of cell-free experiments (Fig. 7, A and
B, lanes 5-8), we first combined the cytosol and
the mitochondria (i.e. Cyto + Mito) and then
activated the mixture with cyt. c. At the end, the mitochondrial
pellets were separated from the cytosol, and caspase activation was
assessed by Western blotting. As shown in Fig. 7, A and
B (lanes 5 and 6), simple
co-incubation of the cytosol with the mitochondria did not result in
procaspase-9 or procaspase-3 activation. However, stimulation with cyt.
c resulted in complete procaspase-9 activation (Fig.
7A, lane 7), just as stimulating cytosol alone
with cyt. c. Significantly, nearly equal amounts of the cleaved p37/p35
bands were now detected in the mitochondrial pellet (Fig.
7A, lane 8), and both the cytosolic and the
mitochondrial p37/p35 bands were roughly half those when cytosol alone
was activated with cytochrome c (Fig. 7A, compare lanes 7 and 8 versus lane
4). These results suggest that ~50% of the cyt. c-activated
caspase-9 in the cytosol translocated to the mitochondria. Likewise,
cyt. c alone activated procaspase-3 in the cytosol and the mitochondria
to generate the p24 and p20 bands and a small amount of p17 (Fig.
7B, lane 7). Surprisingly, only the active p20
fragment translocated to the mitochondria (Fig. 7B,
lane 8).
Next, we ran a time course experiment in which we first made cyt.
c-activated cytosol and then co-incubated it with the untreated mitochondria for 1 or 3 h. As shown in Fig. 7C
(lanes 1-3), no caspase-9 or caspase-3 activation was
observed in unactivated cytosol or unactivated cytosol + mitochondria
mix. However, the cytosolic procaspase-9 was again completely activated
by cyt. c (Fig. 7C, lane 4). Co-incubation of the
cyt. c-activated cytosol with the untreated mitochondria for 1 h
led ~50% of the p37/p35 bands to translocate to the mitochondria
(Fig. 7C, lanes 4-6). Co-incubation for 3 h
rendered all of the p37 band and most of the p35 band to translocate to
the mitochondria (Fig. 7C, lanes 7 and
8 versus lanes 5 and 6). In
the meantime, there was a decrease in the mitochondrial procaspase-9
band (Fig. 7C, compare lane 8 versus
lane 6), suggesting that procaspase-9 may also have been activated in the mitochondria. Similarly, co-incubation of the cyt.
c-activated cytosol with the mitochondria for 1 h resulted in
specific translocation of the p20 active caspase-3 band to the
mitochondria with a concomitant decrease in the cytosolic p20 (Fig.
7D, lanes 4-6). There was also a decrease in the
mitochondrial procaspase-3 (Fig. 7D, compare lane
6 versus lane 3). Co-incubation for 3 h
resulted in the accumulation of more p20 band as well as the p17 and
p24 bands in the mitochondria (Fig. 7C, lanes 7 and 8 versus lanes 5 and
6), without a further decrease in the mitochondrial
procaspase-3 (Fig. 7D, lane 8 versus lane 6).
Mitochondrial Procaspases Can Be Activated in the
Organelle--
The above cell-free reconstitution experiments have
established that the mitochondrial active caspase-9 and -3 result
mostly from translocation. Some evidence suggests that the
mitochondrial procaspases may also become activated by
translocated active caspases (see above). Therefore, we performed
several additional cell-free experiments to address further this
possibility. First, we performed a cell-free recombination experiment
in which the freshly isolated mitochondria were co-incubated with
either untreated or BMD188-treated GM701 cell cytosol and then
separated the mitochondrial pellet from the cytosol. The rationale is
that the BMD188-activated caspases in the cytosol may directly activate
the mitochondrially localized procaspases, or translocate to the
mitochondria, or both. As shown in Fig.
8A, the BMD188-treated cytosol
had active caspase-9 (p37/p35) and caspase-3 (p20/p17) (lane
5), whereas the control cytosol had neither (lane 3).
Correspondingly, the control cytosol had more procaspases than the
BMD188-activated cytosol (Fig. 8A, compare lane 3 versus lane 5). After co-incubation for 1 h,
nearly identical amounts of both procaspase-9 or -3 and their activated
forms were recovered from the supernatant (Fig. 8A, compare
lane 6 versus 5). Nevertheless,
activated forms of both caspase-9 and caspase-3 were identified in the
mitochondrial pellets concomitant with a decrease in the corresponding
procaspases in the mitochondria (Fig. 8A, compare lane
2 versus lane 1). When the co-incubation was
extended to 2 h, a further decrease in the mitochondrial
procaspases was observed (not shown). These results suggest that, in
this cell-free system, small amounts of the activated caspases in the cytosol may have permeabilized the OMM (48, 49), gained access to and
subsequently activated the mitochondrially localized procaspase-9 and
-3 in the organelle.
To explore further this possibility, we directly incubated the intact
mitochondria with recombinant active caspase-3 to see whether the
mitochondrially localized procaspase-9 or -3 can ever be
activated in the organelle. As shown in Fig. 8B, unactivated cytosol (lane 1) and mitochondria (lane 2) showed
only procaspase-9 and procaspase-3 bands. The recombinant caspase-3
showed p20, p17, and p12 bands (Fig. 8B, lane 3).
Co-incubation of the cytosol with active caspase-3 generated, as
expected, the p37 active caspase-9, resulting from procaspase 9 cleavage at Asp330 by caspase-3 (40). Similarly,
co-incubation of the mitochondria with active caspase-3 also generated
the p37 active caspase-9 concomitant with a decrease of procaspase-9,
both of which were detected exclusively in the mitochondrial pellet
(Fig. 8B, compare lane 6 with lane 2).
These results suggest that exogenously added active caspase-3 entered
the mitochondria and activated the procaspase-9 in the organelle.
Surprisingly, co-incubation of the cytosol with active caspase-3 did
not lead to obvious caspase-3 activation in the cytosol (Fig.
8B, compare lane 4 with lane 3). When
the mitochondria were incubated with the active caspase-3, most p12 was
recovered from the mitochondrial pellet (Fig. 8B, lane
6 versus 3), and little p17 was recovered
from the supernatant (Fig. 8B, lane 5 versus lane 3), whereas slightly more p20 was
recovered from the supernatant (Fig. 8B, lane 5 versus lane 3), suggesting that most of the exogenously
supplied p17/p12 (but not p20) caspase-3 translocated to the
mitochondria. However, there was a prominent increase in the level of
p17 in the mitochondrial pellet concomitant with decreased procaspase-3
as well as p20 (Fig. 8B, lane 6 versus lanes 2 and 3). Since the p17 fragment comes
mainly from caspase-3-mediated autocatalysis (44, 45), these results,
together, suggest the following: 1) the p17/12 caspase-3 enters the
mitochondria to activate the procaspase-9 and -3 in the organelle, and
2) the activated mitochondrial caspase-9 (i.e. the p37) may
further activate the mitochondrial procaspase-3, which autocleaves more
procaspase-3 to generate more p17.
The current study focuses on the mitochondria-associated active
caspase-9 and caspase-3. The multifaceted results allow us to present a
model (Fig. 9) to explain their location,
origin, relationship with the cytosolic counterparts, and potential
biological functions. In response to apoptotic stimulation, several
mitochondrial proteins such as the IMS protein cyt. c and the matrix
protein Hsp60 are released, involving CsA-sensitive MMP. In certain
apoptotic systems, the mitochondrial procaspases are similarly released into the cytosol, some of which translocate to the perinuclear area. In
a similar fashion, Apaf-1, which is located exclusively in the cytosol,
also translocates to the perinuclear region (Fig. 9). The released cyt.
c triggers apoptosome formation in the cytosol leading to caspase-9
and, subsequently, caspase-3 activation. The activated caspase-9 and -3 rapidly translocate back to the mitochondria where they may further
activate residual or other resident procaspases in the organelle,
degrade mitochondrial proteins, disintegrate mitochondria, and help
drive the apoptotic process to completion.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
, procaspase-1 translocates to the nucleus where it is
proteolytically activated (22, 23). Upon treatment with tunicamycin,
some activated caspase-12 translocates to or around the nuclei of
apoptotic cells (24). In some experimental systems, the mitochondrially
localized procaspase-2 and -3, upon activation, translocate to the
nucleus (14, 15, 17). Activated caspase-7 has been shown to be
associated exclusively with the mitochondrial/microsomal fractions
(25). Activated forms of caspase-2 and caspase-9 have been detected in
the mitochondria (17). Activated caspase-2 has also been detected in
apoptotic nuclei (26). Upon induction of apoptosis, mitochondrial
procaspase-9 translocates to the cytosol and nucleus in both cell
culture and animal model systems (17, 21). Similarly, activated
caspase-3 has been detected in normal and apoptotic nuclei (27-29). In
all these apoptotic systems, it is generally thought that procaspases
"stored" in various subcellular compartments are released, upon
apoptosis induction, and become activated in the cytosol or that the
cytosolically activated caspases translocate to various organelles to
participate in apoptosis. It is still unclear whether the procaspases
localized in the organelles (e.g. mitochondria) can
ever be activated in situ. A pertinent
philosophical question is why these procaspases have to be
"imported" into these organelles if they can only be activated in
the cytosol?
MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
Primary antibodies used in this study
RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
View larger version (17K):
[in a new window]
Fig. 1.
Activated mitochondria possess caspase
activity. A, mitochondria, cytosol, and whole cell
lysate were prepared from equal numbers of PC3 cells (i.e.
107 cells for each fraction) treated with BMD188 (40 µM) for the indicated time intervals and used to measure
DEVDase activity using 50 µg of protein and 10 µM
Ac-DEVD-AFC substrate. The DEVDase activity was expressed as fold
activation over the control, i.e. time 0. The data represent
mean ± S.E. derived from three independent experiments.
B, cell-free reconstitution experiment. One hundred µg of
mitochondria (mito) was prepared from either control or
BMD188-treated (40 µM; 90 min) PC3 cells. The
mitochondria, either lysed (using Nonidet P-40) or unlysed, were either
directly utilized in the DEVDase measurement (lanes 1-4) or
first co-incubated with 100 µg of cytosol prepared from untreated PC3
cells (lanes 6-9) for 1 h at 37 °C before
incubation with 30 µM DEVD-AFC substrate (1 h at
37 °C). Lane 5 was the untreated cytosol alone.
Lane 10 was caspase-3 activity measured with 100 µg of
whole cell lysate from the same batch of PC3 cells treated with BMD188.
The data represent mean ± S.E. derived from 3 experiments.
C, effects of caspase inhibitors on DEVDase activity. PC3
cells were pretreated with ethanol (vehicle control), Z-DEVD-fmk (50 µM), or Z-VAD-fmk (50 µM) for 1 h
followed by BMD188 (40 µM; 2 h) treatment.
Subsequently, mitochondrial and cytosolic fractions (50 µg each) were
used for DEVDase activity assay by incubating with 10 µM
Ac-DEVD-AFC. The data represent mean ± S.E. derived from five
independent experiments.
View larger version (21K):
[in a new window]
Fig. 2.
Caspase activation in
vitro. A, caspase activity expressed as the
raw fluorescence unit as a result of Ac-DEVD-AFC hydrolysis. One
hundred µg of cytosol or mitochondria (mito) from
untreated (control) or BMD188-treated (40 µM;
90 min) PC3 cells was incubated with 30 µM Ac-DEVD-AFC
substrate at 37 °C for 0 (i.e. immediate measurement
following mixing), 30, 60, 90, and 120 min. The fluorescence measured
at A505 was directly plotted as a function of
time. Triplicate samples were run for each time point, and the data
represent mean ± S.D. Note that the mitochondrial samples had
lower background fluorescence levels (i.e. the values at
time 0) than the cytosolic samples; the former was 0.4-0.9 and the
latter was 5-7.5. B, caspase activity expressed as fold
activation. The data obtained in A were plotted as fold
activation that was derived by dividing the mean fluorescence value at
each time point by the mean fluorescence value at time 0. Thus, the
fold activation at time 0 was considered as 1. C, caspase
activity expressed as corrected fluorescence, which was derived by
dividing the mean fluorescence value at each time point in
BMD188-treated mitochondria or cytosol by the mean fluorescence value
at corresponding time point in control mitochondria or cytosol,
respectively. Therefore, DEVDase activities at all time points in the
control mitochondria and cytosol were 1 (not plotted).
View larger version (54K):
[in a new window]
Fig. 3.
Proteolytic activation of procaspase-9 and -3 and redistribution of caspases and Apaf-1 during apoptosis.
Western blot analysis of the whole cell lysate, cytosolic and
mitochondrial fractions from PC3 (A) or GM701 cells
(B) treated with BMD188, LNCaP cells subjected to serum
starvation (C), or GM701 cells treated with staurosporine
(STS) (D). Thirty (cytosolic) or 60 (mitochondrial) µg of proteins was used in Western blotting for
caspase-9, caspase-3, Apaf-1, and actin, as indicated. PARP cleavage
and apoptosis were determined as described under "Materials and
Methods." The asterisks on the left of
A and B are novel or nonspecific bands detected
by the antibodies against caspase-9 or caspase-3. All data are
representative of at least three independent experiments.
View larger version (38K):
[in a new window]
Fig. 4.
BMD188-induced translocation of
procaspase-9, procaspase-3, and Apaf-1 to the perinuclear area.
GM701 cells treated with BMD188 (40 µM; 1 h) were
processed for immunolabeling of caspase-9 (A-D), caspase-3
(E-H), or Apaf-1 (I-L). Nuclei were
counterstained with DAPI. Microphotographs shown are representative of
three independent experiments. Bar, 10 µm.
View larger version (26K):
[in a new window]
Fig. 5.
Active caspase-9 and caspase-3 are localized
in the IMS of the mitochondria. A, mitochondria
prepared from GM701 cells either untreated (lanes 1-3) or
treated with BMD188 (40 µM; 2 h; lanes
4-6) were subjected to proteinase K (Pro-K) digestion
in the presence or absence of Triton X-100 as described under
"Materials and Methods." CTL, control. At the end
of digestion, samples were resolved by SDS-PAGE and immunoblotted for
caspase-9, caspase-3, and VDAC. The dot-circled bands
represent a degraded product of caspase-3 by proteinase K; and the
asterisk indicates the unknown p19 band. B,
mitochondria from control (lanes 1 and 2) and
BMD188-treated (lanes 3 and 4) GM701 cells were
subjected to alkali extraction as described under "Materials and
Methods." At the end of treatment, the supernatant (S) and
pellet (P) were collected by centrifugation and used in
Western blotting for caspase-9 and -3, Hsp60, and VDAC. All data are
representative of 2-3 independent experiments.
View larger version (49K):
[in a new window]
Fig. 6.
CsA inhibits both initial mitochondrial
protein release and later caspase association with the
mitochondria. PC3 cells were pretreated with vehicle
(control), CsA (10 µM), or Z-VAD-fmk (50 µM) for 1 h followed by BMD188 (40 µM)
treatment in the presence of these inhibitors for the times indicated.
At the end of the treatment, cells were harvested for subcellular
fractionation. Twenty five µg of cytosolic or mitochondrial proteins
were used in Western blotting of holo-cyt. c, Hsp60, caspase-9, or
caspase-3. The asterisks on the left indicate
unknown caspase-9 or -3 bands. Data are representative of 2-3
independent experiments.
View larger version (27K):
[in a new window]
Fig. 7.
Cell-free activation and
translocation of caspase-9 and caspase-3. Mitochondria and cytosol
were prepared from untreated GM701 cells. Caspase activation and
translocation to mitochondria were assessed by Western blotting.
A and B, cell-free activation of caspase-9
(A) or caspase-3 (B) initiated by cyt. c. Freshly
prepared mitochondria (25 µg) or cytosol (40 µg) was individually
incubated with none or bovine heart cyt. c at 37 °C for 2 h
(lanes 1-4). In a parallel experiment, cytosol
(Cyto) and mitochondria (Mito) were co-incubated
with none or cyt. c (lanes 5-8). At the end of the
incubation, mitochondria were pelleted, and cytosolic and mitochondrial
samples were separated and probed for caspase-9 (A) or
caspase-3 (B) (lanes 5-8). C and
D, time course of caspase activation and translocation. Cyt.
c-activated (lanes 4-8) (2 h at 37 °C) cytosol (40 µg)
was co-incubated with fresh mitochondria (40 µg) at 37 °C for 1 or
3 h. After incubation, mitochondrial pellet (P) and
supernatant (S) were subjected to Western blotting for
caspase-9 (C) or caspase-3 (D). As controls,
unactivated cytosol (lane 1), and the supernatant and the
pellet obtained from co-incubated unactivated cytosol and unactivated
mitochondria (lanes 2 and 3, respectively), were
also run on the gel. Data are representative of at least 3 independent
experiments.
View larger version (36K):
[in a new window]
Fig. 8.
Activation of the mitochondrial procaspases
in the organelle. A, cell-free recombination
experiments to show that the active caspases in the BMD188-actived
cytosols may activate the mitochondrially localized procaspases.
Cytosol (cyto) and mitochondria (mito) were
isolated from control or BMD188-treated GM701 cells. Control or treated
cytosol (30 µg) was then co-incubated with control mitochondria (40 µg) for 1 h at 37 °C. At the end of incubation, cytosol
(S) and mitochondria (P) were separated by
centrifugation followed by Western blotting for caspase-9, and -3. The
asterisk indicates the unknown p19 band. B,
recombinant active caspase-3 can activate the mitochondrially localized
procaspase-9 and procaspase-3. Cytosol (40 µg; lane 1) and
mitochondria (30 µg; lane 2), freshly prepared from
untreated GM701 cells, were incubated with recombinant active caspase-3
(lanes 4-6, respectively). S and P
refer to the supernatant and mitochondrial pellet, respectively, at the
end of the incubation. As a control, an aliquot (5 ng) of the
recombinant caspase-3 was also run on the same gel (lane 3).
Data are representative of 3 independent experiments.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
View larger version (25K):
[in a new window]
Fig. 9.
A hypothetical model illustrating the dynamic
movements of various apoptosis-related molecules in different
subcellular compartments during apoptosis. Casp., caspase.
See text for detailed discussion.
Active Caspases in the Mitochondria: Unlikely Involvement of Apaf-1 in the Activation of Procaspase-9 in the Organelle-- A multitude of studies have demonstrated the presence of pro- and activated caspases in the mitochondria (14, 17-19, 21, 27, 28, 50), although this phenomenon has been challenged recently (51). The reason for this discrepancy remains unclear, but the negative results may likely result from cell type-specific variations, different antibodies used, insufficient protein loading, and utilization of digitonin-permeabilized mitochondria (51). Our well controlled experiments using mitochondria prepared by either Percoll gradient purification (Fig. 2) or differential centrifugation (the rest) demonstrate the presence of procaspases in unstimulated mitochondria and, more importantly, of activated caspases in apoptosis-stimulated mitochondria. Like their procaspase counterparts, the activated caspase-9 and -3 are localized in the IMS of the mitochondria (Fig. 5).
Our recent observation (30) that a wide diversity of apoptotic inducers cause an early up-regulation and accumulation of cyt. c in the mitochondria raises the following intriguing question. Could this increased mitochondrial cyt. c lead to procaspase-9 activation right in the organelle analogous to apoptosome-mediated procaspase-9 activation in the cytosol? Several pieces of evidence make our initial hypothesis unlikely. First, in all our apoptotic models the initial appearance of the activated caspase-9 in the mitochondria occurs either following or concomitant with the caspase-9 activation in the cytosol without proteolytic degradation of the mitochondrial procaspase-9 (Fig. 3). These observations suggest that caspase-9 activation is initiated in the cytosol. Second, Apaf-1, the key adaptor molecule in apoptosome-mediated caspase-9 activation, is exclusively expressed in the cytosol, consistent with the observations of other investigators (46), and is never found in the mitochondria. Third, even after apoptotic stimulation, no association of Apaf-1 with the mitochondrial fractions is observed (Fig. 3, A-D). Finally, cell-free reconstitution experiments demonstrate that cyt. c does not directly activate the mitochondrial procaspase-9 although it completely activates the cytosolic procaspase-9 (Fig. 7A), thus confirming the lack of Apaf-1 in the mitochondria. These observations make it clear that procaspase-9 cannot be activated inside the mitochondria in an Apaf-1/apoptosome-dependent manner.
Interestingly, in all the apoptotic models studied here, cytosolic Apaf-1 rapidly translocates to the perinuclear area, similar to recent findings (52) in different mammalian cells. Remarkably, the Apaf-1 homologue in Caenorhabditis elegans, CED-4, also translocates to the nuclear membrane during apoptosis (53). What could be the functions of this translocation? One clue is that, in addition to Apaf-1, cyt. c (52), procaspase-9 and -3 (this study), and many other caspases (22-24, 26, 28, 29) also become associated with the nucleus during apoptosis. It is possible that these molecules move together to assemble functional apoptosomes to induce caspase activation in or around the nucleus in order to disassemble the nuclear cytoplasmic barrier (54) and catalyze the systematic degradation of the nucleus.
Active Caspases in the Mitochondria Are Derived Mostly from the Translocation-- If the Apaf-1-containing apoptosome is not involved, then how is the mitochondrial active caspase-9 brought about? Although Apaf-1-independent mechanisms recently emerged (11-13) could be involved, the most plausible explanation is that the active caspase-9 in the mitochondria comes from translocation from the cytosol. Supporting evidence comes from PC3 or GM701 cells treated with BMD188 in which increasing levels of the activated caspase-9 are seen in the mitochondria in the absence of corresponding decreases in the mitochondrial procaspase-9 levels (Fig. 3, A and B). Instead, the cytosolic procaspase-9 continuously decreases without a corresponding increase in the active caspase-9 (Fig. 3, A and B). More importantly, in PC3 cells the cytosolic caspase-9 activation occurs prior to the mitochondrial caspase-9 activation (Fig. 3A). Cell-free reconstitution experiments also provide clear-cut evidence that the cytosolically activated caspase-9 can translocate to the mitochondria. Translocation seems to be a temperature- and energy-dependent process; translocation is decreased at room temperature and stopped at 4 °C.2
The mitochondria-associated active caspase-3 generally appears at the same time when the cytosolic caspase-3 becomes activated (Fig. 3, A-D), but at least in some cases, an early translocation of the activated cytosolic caspase-3 to the mitochondria can be suggested. For example, in BMD188-treated PC3 cells, the mitochondrial caspase-3 activation is observed at 45 min post-treatment (Figs. 1, 2, and 3A). However, the active mitochondrial caspase-9 is not observed by this time (Fig. 3A), suggesting that the active caspase-3 in the mitochondria probably comes from translocation from the cytosol. In addition, increasing amounts of both active caspase-3 (i.e. the p20 fragment) as well as the procaspase-3 are observed in the mitochondria (Fig. 3A). Finally, cell-free reconstitution experiments show that the cytosolically activated caspase-3 can indeed translocate to the mitochondria (Fig. 7).
How may activated caspases translocate to the IMS of the mitochondria? It is still unclear how various procaspases, which generally lack an identifiable mitochondria-targeting sequence (51), get into the IMS. Evidence presented here suggests that a CsA-inhibitable mechanism(s) seems to be responsible, at least partially, for both the early release of the mitochondrial proteins such as cyt. c and Hsp60 as well as for the later translocation of the activated caspases back to the mitochondria. CsA, which has been shown to inhibit apoptosis in multiple model systems, is generally thought to block apoptosis by inhibiting MMP (48, 49). CsA has been shown recently (55) to also inhibit the remodeling of the mitochondrial cristae and consequently inhibit cyt. c release. How mitochondrial proteins are released from the mitochondria is still controversial, but it seems to involve different types of channels consisting of pro-apoptotic Bcl-2 proteins such as Bax and Bak and some resident mitochondrial proteins such as VDAC (reviewed in Refs. 48 and 49). Consistent with our earlier data (30), CsA inhibits the early release of both cyt. c and Hsp60 (Fig. 6), thus suggesting the potential involvement of MMP in this process. Interestingly, CsA also appears to inhibit the later translocation of active caspases as it specifically reduces their levels in the mitochondria (Fig. 6). These results suggest that translocation of the activated caspases back to the mitochondria might use a CsA-sensitive mechanism(s) similar to those utilized for the initial mitochondrial protein release. It is unclear how the activated cytosolic caspase-9, most of which is thought to remain bound to the apoptosome (38-40), gets to the mitochondria. The supramolecular openings formed by Bid, Bax, and the mitochondrial membrane lipids can release molecules of 2,000 kDa (56), which should be sufficient to "entertain" the 700-kDa to 1.4-MDa apoptosome. However, Apaf-1 is never detected in the mitochondria. It is possible that some activated caspase-9, especially those activated by caspase-3, may not be apoptosome-bound and thus be free to translocate to the mitochondria.
Recent evidence (6-10) suggests that, in some apoptotic systems, caspase-2 activation precedes or may even be required for the compromise of the mitochondrial integrity such as cyt. c release. Our data suggest that, in our systems, caspase activation occurs after the disruption of the mitochondrial integrity and function (30) (Fig. 6 of this study). More importantly, Z-VAD does not affect the initial release of the mitochondrial proteins (Fig. 6). Since Z-VAD inhibits caspase activation, as expected, but the activated caspase-9 and -3 are still observed in the mitochondria, the reduced levels of the mitochondria-associated active caspases (Fig. 6) mostly likely are caused by the overall inhibition of caspase activation rather than inhibition of translocation.
Active Caspases in the Mitochondria May Also Derive Partly from the Caspase-mediated Activation in the Organelle-- Conceptually, translocated active caspases may subsequently activate the mitochondrial procaspases in the organelle. Several pieces of evidence support this possibility. First, late during apoptosis most mitochondrial procaspase-9 (Fig. 3D) and procaspase-3 (Fig. 3, B-D) becomes completely proteolyzed. Second, cell-free reconstitution experiments suggest that the mitochondrial procaspase-9 and -3 may become proteolytically activated in the organelle (Fig. 7, C and D). Third, cell-free recombination experiments also suggest direct procaspase activation in the mitochondria (Fig. 8A). Finally, both mitochondrial procaspase-9 and -3 can be activated by recombinant active caspase-3 (Fig. 8B). Various cell-free experiments using intact mitochondria (Figs. 7 and 8) suggest that a small amount of activated caspases may permeabilize the OMM (47, 48), enter the IMS, and activate the mitochondrially localized procaspases. Under continuous apoptotic stimulation presumably the MMP persists, thus allowing the access of the cytosolically activated caspases to the IMS without the obvious need for caspase-mediated permeabilization, which explains why CsA but not Z-VAD inhibits caspase translocation to the mitochondria (Fig. 6).
The Potential Biological Functions of the Mitochondrially Localized Active Caspases-- Multiple pieces of evidence suggest that the active caspases in the mitochondria may play a role in apoptosis. First, significant amounts of activated caspase-9 and -3 are accumulated in the mitochondria, especially late during apoptosis (Fig. 3, A-D). In support, significant caspase activities are detected in the mitochondria (Figs. 1 and 2; and data not shown). Second, in the reconstitution experiments, activated caspases preferentially translocate to the mitochondria (Fig. 7). Third, the preferential association of the active caspase-3 with the mitochondria seems to be essential for the complete activation of caspase-9.2 Finally, the cytosolic procaspase-3 does not seem to be efficiently activated by exogenous active caspase-3 in the absence of the mitochondria (Fig. 8B).
Presumably, the activated caspase-9 and -3 in the mitochondria can play
the following functions. First, they may further activate residual or
other resident procaspases in the organelle (Fig. 9). Thus the
expression of the active caspases in the mitochondria establishes a
positive feedback amplification mechanism. Second, they may degrade
some mitochondrial proteins. It is interesting to note that compared
with the known caspase substrates in the cytosol and other organelles,
few distinct mitochondrial substrates have been identified. Recently,
caspase-9 is shown to be able to degrade certain cellular components
other than caspases (57). Therefore, it is possible that active
caspase-3 as well as caspase-9 in the mitochondria may specifically
degrade some mitochondrial substrates such as the MRC protein
complexes. Third, the mitochondrial active caspase-9 and -3 may further
disintegrate mitochondrial integrity and function such as facilitating
MMP, cyt. c release, and generation of reactive oxygen species (58).
Together these functions help drive the apoptotic process to completion.
![]() |
ACKNOWLEDGEMENTS |
---|
We thank M. King for providing GM701.2-8C cells; Biomide Corp. for BMD188; X. Wang for antibody against Smac; A. Ellis for help with EM; and members of the Tang laboratory for helpful discussions. We also thank S. Bratton for helpful discussions and critically reading the manuscript.
![]() |
FOOTNOTES |
---|
* This work was supported in part by NCI Grant CA 90297 and NIEHS Center Grant ES07784 from the National Institutes of Health and by institutional grants from the University of Texas MD Anderson Cancer Center.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Supported by Department of Defense Postdoctoral Traineeship Award
DAMD17-02-1-0083.
§ To whom correspondence should be addressed: Dept. of Carcinogenesis, University of Texas MD Anderson Cancer Center, Science Park Research Division, Park Rd. 1C, Smithville, TX 78957. Tel.: 512-237-9575; Fax: 512-237-2475; E-mail: dtang@sprd1.mdacc.tmc.edu.
Published, JBC Papers in Press, February 28, 2003, DOI 10.1074/jbc.M300750200
2 D. Chandra and D. G. Tang, unpublished observations.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: PARP, poly(ADP-ribose) polymerase; AFC, 7-amino-4-trifluoromethylcoumarin; Apaf-1, apoptotic protease-activating factor-1; BMD188, a hydroxamic acid compound; cyt. c, cytochrome c; CsA, cyclosporin A; DAPI, 4',6-diamidino-2-phenylindole; IMS, intermembrane space; MADAP, mitochondrial activation-dependent apoptotic pathway; MMP, mitochondrial membrane permeabilization; MRC, mitochondrial respiratory chain; OMM, outer mitochondrial membrane; VDAC, voltage-dependent anion channel; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; Z, benzyloxycarbonyl; PBS, phosphate-buffered saline; MOPS, 4-morpholinepropanesulfonic acid; fmk, fluoromethyl ketone; Pan, pantothenate.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Horvitz, H. R. (1999) Cancer Res. 59, S1701-S1706 |
2. | Salvesen, G. S., and Dixit, V. M. (1997) Cell 91, 443-446[Medline] [Order article via Infotrieve] |
3. |
Thornberry, N. A.,
and Lazebnik, Y.
(1998)
Science
281,
1312-1316 |
4. |
Wang, X.
(2001)
Genes Dev.
15,
2922-2933 |
5. |
Ashkenazi, A.,
and Dixit, V. M.
(1998)
Science
281,
1305-1308 |
6. |
Guo, Y.,
Srinivasula, S. M.,
Druilhe, A.,
Fernandes-Alnemri, T.,
and Alnemri, E. S.
(2002)
J. Biol. Chem.
277,
13430-13437 |
7. |
Paroni, G.,
Henderson, C.,
Schneider, C.,
and Brancolini, C.
(2002)
J. Biol. Chem.
277,
15147-15161 |
8. |
Robertson, J. D.,
Enoksson, M.,
Suomela, M.,
Zhivotovsky, B.,
and Orrenius, S.
(2002)
J. Biol. Chem.
277,
29803-29809 |
9. |
Lassus, P.,
Opitz-Araya, X.,
and Lazebnik, Y.
(2002)
Science
297,
1352-1354 |
10. |
Read, S. H.,
Baliga, B. C.,
Ekert, P. G.,
Vaux, D. L.,
and Kumar, S.
(2002)
J. Cell Biol.
159,
739-745 |
11. | Marsden, V. S., O'Connor, L., O'Reilly, L., Silke, J., Metcalf, D., Ekert, P. G., Huang, D. C. S., Cecconi, F., Kuida, K., Tomaselli, K. J., Roy, S., Nicholson, D. W., Vaux, D., Bouillet, P., Adams, J. M., and Strasser, A. (2002) Nature 419, 634-637[CrossRef][Medline] [Order article via Infotrieve] |
12. |
Rao, R. V.,
Castro-Obregon, S.,
Frankowski, H.,
Schuler, M.,
Stoka, V.,
del Rio, G.,
Bredsen, D. E.,
and Ellerby, H. M.
(2002)
J. Biol. Chem.
277,
21836-21842 |
13. |
Morishima, N.,
Nakanishi, K.,
Takenouchi, H.,
Shibata, T.,
and Yasuhiko, Y.
(2002)
J. Biol. Chem.
277,
34287-34294 |
14. | Zhivotovsky, B., Samali, A., Gahm, A., and Orrenius, S. (1999) Cell Death Differ. 6, 644-651[CrossRef][Medline] [Order article via Infotrieve] |
15. |
Mancini, M.,
Machamer, C. E.,
Roy, S.,
Nicholson, D. W.,
Thornberry, N. A.,
Casciola-Rosen, L. A.,
and Rosen, A.
(2000)
J. Cell Biol.
149,
603-612 |
16. | Nakagawa, T., Zhu, H., Morishima, N., Li, E., Xu, J., Yankner, B. A., and Yuan, J. (2000) Nature 403, 98-103[CrossRef][Medline] [Order article via Infotrieve] |
17. |
Susin, S. A.,
Lorenzo, H. K.,
Zamzami, N.,
Marzo, I.,
Brenner, C.,
Larochette, N.,
Prevost, M. C.,
Alzari, P. M.,
and Kroemer, G.
(1999)
J. Exp. Med.
189,
381-394 |
18. |
Mancini, M.,
Nicholson, D. W.,
Roy, S.,
Thornberry, N. A.,
Peterson, E. P.,
Casiola-Rosen, L. A.,
and Rosen, A.
(1998)
J. Cell Biol.
140,
1485-1495 |
19. | Samali, A., Zhivotovsky, B., Jones, D. P., and Orrenius, S. (1998) FEBS Lett. 431, 167-169[CrossRef][Medline] [Order article via Infotrieve] |
20. |
Quin, Z. H.,
Wang, Y.,
Kikly, K. K.,
Sapp, E.,
Kegel, K. B.,
Aronin, N.,
and DiFiglia, M.
(2001)
J. Biol. Chem.
276,
8079-8086 |
21. |
Krajewski, S.,
Krajewska, M.,
Ellerby, L. M.,
Welsh, K.,
Xie, Z. H.,
Deveraux, Q. L.,
Salvesen, G. S.,
Bredesen, D. E.,
Rosenthal, R. E.,
Fiskum, G.,
and Reed, J. C.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
5752-5757 |
22. | Nakagawara, A., Nakamura, Y., Ikeda, H., Hiwasa, T., Kuida, K., Su, M. S., Zhao, H., Cnaan, A., and Sakiyama, S. (1997) Cancer Res. 57, 4578-4584[Abstract] |
23. |
Mao, P.-L.,
Jiang, Y.,
Wee, B. Y.,
and Porter, A. G.
(1998)
J. Biol. Chem.
273,
23621-23624 |
24. | Fujita, E., Kouroku, Y., Jimbo, A., Isoai, A., Maruyama, K., and Momoi, T. (2002) Cell Death Differ. 9, 1108-1114[CrossRef][Medline] [Order article via Infotrieve] |
25. |
Chandler, J. M.,
Cohen, G. M.,
and MacFarlane, M.
(1998)
J. Biol. Chem.
273,
10815-10818 |
26. |
Colussi, P. A.,
Harvey, N. L.,
and Kumar, S.
(1998)
J. Biol. Chem.
273,
24535-24542 |
27. | Costantini, P., Bruey, J.-M., Castedo, M., Metivier, D., Loeffler, M., Susin, S. A., Ravagnan, L., Zamzami, N., Garrido, C., and Kroemer, G. (2002) Cell Death Differ. 9, 82-88[CrossRef][Medline] [Order article via Infotrieve] |
28. | Krajewska, M., Wang, H.-G., Krajewski, S., Zapata, J. M., Shabaik, A., Gascoyne, R., and Reed, J. C. (1997) Cancer Res. 57, 1605-1613[Abstract] |
29. |
Martins, L. M.,
Kottke, T.,
Mesner, P. W.,
Basi, G. S.,
Sinha, S.,
Frigon, N., Jr.,
Tatar, E.,
Tung, J. S.,
Brynt, K.,
Takahashi, A.,
Svingen, P. A.,
Madden, B. J.,
McCormick, D. J.,
Earnshaw, W. C.,
and Kaufmann, S. H.
(1997)
J. Biol. Chem.
272,
7421-7430 |
30. |
Chandra, D.,
Liu, J.-W.,
and Tang, D. G.
(2002)
J. Biol. Chem.
277,
50842-50854 |
31. | Tang, D. G., Li, L., Zhu, Z., and Joshi, B. (1998) Biochem. Biophys. Res. Commun. 242, 380-384[CrossRef][Medline] [Order article via Infotrieve] |
32. |
Joshi, B.,
Li, L.,
Taffe, B. G.,
Zhu, Z.,
Wahl, S.,
Tian, H.,
Ben-Josef, E.,
Taylor, J. D.,
Porter, A. T.,
and Tang, D. G.
(1999)
Cancer Res.
59,
4343-4355 |
33. | Petit, P. X., O'Connor, J. E., Grunwald, D., and Brown, S. C. (1990) Eur. J. Biochem. 194, 389-397[Abstract] |
34. | Tang, D. G., Li, L., Chopra, D. P., and Porter, A. T. (1998) Cancer Res. 58, 3466-3479[Abstract] |
35. |
Antonsson, A.,
Montessuit, S.,
Sanchez, B.,
and Martinous, J.-C.
(2001)
J. Biol. Chem.
276,
11615-11623 |
36. |
Slee, E. A.,
Harte, M. T.,
Kluck, R. M.,
Wolf, B. B.,
Casiano, C. A.,
Newmeyer, D. D.,
Wang, H. G.,
Reed, J. C.,
Nicholson, D. W.,
Alnemri, E. S.,
Green, D. R.,
and Martin, S. J.
(1999)
J. Cell Biol.
144,
281-292 |
37. | Bratton, S. B., Walker, G., Roberts, D. L., Cain, K., and Cohen, G. M. (2001) Cell Death Differ. 8, 425-433[CrossRef][Medline] [Order article via Infotrieve] |
38. | Srinivasula, S. M., Ahmad, M., Fernandez-Alnemri, T., and Alnemri, E. S. (1998) Mol. Cell 1, 949-957[Medline] [Order article via Infotrieve] |
39. | Srinivasula, S. M., Hedge, R., Saleh, A., Dhatta, P., Shiozaki, E., Chai, J., Lee, R. A., Robbins, P. D., Fernandez-Alnemri, T., Shi, Y., and Alnemri, E. S. (2001) Nature 410, 112-116[CrossRef][Medline] [Order article via Infotrieve] |
40. |
Bratton, S. B.,
Walker, G.,
Srinivasula, S. M.,
Sun, X. M.,
Butterworth, M.,
Alnemri, E. S.,
and Cohen, G. M.
(2001)
EMBO J.
20,
998-1009 |
41. | Budihardjo, I., Oliver, H., Lutter, M., Luo, W., and Wang, X. (1999) Annu. Rev. Cell Dev. Biol. 15, 269-290[CrossRef][Medline] [Order article via Infotrieve] |
42. |
Chalfant, C. E.,
Rathman, K.,
Pinkerman, R. L.,
Wood, R. E.,
Obeid, L. M.,
Ogretmen, B.,
and Hannun, Y. A.
(2002)
J. Biol. Chem.
277,
12587-12595 |
43. |
Angelastro, J. M.,
Moon, N. Y.,
Liu, D. X.,
Yang, A.-S.,
Greene, L. A.,
and Franke, T. F.
(2001)
J. Biol. Chem.
276,
12190-12200 |
44. |
Li, S.,
Zhao, Y.,
He, X.,
Kim, T.-H.,
Kuharsky, D. K.,
Rabinowich, H.,
Chen, J.,
Du, C.,
and Yin, X.-M.
(2002)
J. Biol. Chem.
277,
26912-26920 |
45. |
Deng, Y.,
Lin, Y.,
and Wu, X.
(2002)
Genes Dev.
16,
33-45 |
46. |
Hausmann, G.,
O'Reilly, L. A.,
van Driel, R.,
Beaumont, J. G.,
Strasser, A.,
Adams, J. M.,
and Huang, D. C.
(2000)
J. Cell Biol.
149,
623-634 |
47. | Debatin, K. M., Poncet, D., and Kroemer, G. (2002) Oncogene 21, 8786-8803[CrossRef][Medline] [Order article via Infotrieve] |
48. | van Loo, G., Saelens, X., van Gurp, M., MacFarlane, M., Martin, S. J., and Vandennabeele, P. (2002) Cell Death Differ. 9, 1031-1042[CrossRef][Medline] [Order article via Infotrieve] |
49. | Jemmerson, R., LaPlante, B., and Treeful, A. (2002) Cell Death Differ. 9, 538-548[CrossRef][Medline] [Order article via Infotrieve] |
50. |
Krebs, J. F.,
Armstrong, R. C.,
Srinivasan, A.,
Aja, T.,
Wong, A. M.,
Aboy, A.,
Sayers, R.,
Pham, B.,
Vu, T.,
Hoang, K.,
Karanewsky, D. S.,
Leist, C.,
Schmitz, A.,
Wu, J. C.,
Tomaselli, K. J.,
and Fritz, L. C.
(1999)
J. Cell Biol.
144,
915-926 |
51. | van Loo, G., Saelens, X., Matthijssens, F., Schotte, P., Beyaert, R., Declercq, W., and Vandenabeele, P. (2002) Cell Death Differ. 9, 1207-1211[CrossRef][Medline] [Order article via Infotrieve] |
52. | Ruiz-Vela, A., Gonzalez, G., de Buitrago, G., and Martinez-A, C. (2002) FEBS Lett. 517, 133-138[CrossRef][Medline] [Order article via Infotrieve] |
53. |
Chen, F.,
Hersh, B. M.,
Conradt, B.,
Zhou, Z.,
Riemer, D.,
Gruenbaum, Y.,
and Horvitz, H. R.
(2000)
Science
287,
1485-1489 |
54. |
Faleiro, L.,
and Lazebnik, Y.
(2000)
J. Cell Biol.
151,
951-960 |
55. | Scorrano, L., Ashiya, M., Buttle, K., Weiler, S., Oakes, S. A., Mannella, C. A., and Korsmeyer, S. J. (2002) Dev. Cell 2, 55-67[CrossRef][Medline] [Order article via Infotrieve] |
56. | Kuwana, T., Mackey, M. R., Perkins, G., Ellisman, M. H., Latterich, M., Schneiter, R., Green, D. R., and Newmeyer, D. D. (2002) Cell 111, 331-342[Medline] [Order article via Infotrieve] |
57. |
Nakanishi, K.,
Maruyama, M.,
Shibata, T.,
and Morishima, N.
(2001)
J. Biol. Chem.
276,
41237-41244 |
58. |
Ricci, J.-E.,
Gottlieb, R. A.,
and Green, D. R.
(2003)
J. Cell Biol.
160,
65-75 |